Therapy options in pulmonary alveolar proteinosis

Therapeutic Advances in Respiratory Disease
Maurizio LuisettiBruce C Trapnell

Abstract

Pulmonary alveolar proteinosis is a rare condition characterized by the accumulation of lipoproteinaceous material within the airspaces, resulting in impaired gas transfer, and clinical manifestations ranging from asymptomatic to severe respiratory failure. To the best of the authors' knowledge, there are only a few conditions whose natural history has been so dramatically changed by the influence of advances in basic science, clinical medicine, and translational research in therapeutic approaches. Whole-lung lavage is the current standard of care and it plays a critical role as a modifier factor of the natural history of proteinosis. That notwithstanding, the identification of autoantibodies neutralizing granulocyte-macrophage colony-stimulating factor in serum and lung of patients affected by the form of proteinosis previously referred to as idiopathic, has opened the way to novel therapeutic options, such as supplementation of exogenous granulocyte-macrophage colony-stimulating factor, or strategies aimed at reducing the levels of the autoantibodies. The aim of this paper is to provide an updated review of the current therapeutic approach to proteinosis.

Associated Clinical Trials

References

Jun 1, 1987·Mayo Clinic Proceedings·U B PrakashH M Marsh
Jan 1, 1969·British Journal of Diseases of the Chest·J M Davidson, W M Macleod
Jun 1, 1968·The American Journal of Medicine·P L AroraR L Mayock
Nov 1, 1965·Annals of Internal Medicine·J RamirezW C Ball
May 1, 1983·Thorax·R M Du BoisM A Branthwaite
Jun 7, 1994·Proceedings of the National Academy of Sciences of the United States of America·E StanleyA R Dunn
Sep 1, 1996·American Journal of Respiratory and Critical Care Medicine·A AlbertiA Baritussio
Dec 19, 1996·The New England Journal of Medicine·J F SeymourM C Pain
Nov 21, 1998·Chest·L S GoldsteinJ K Stoller
May 20, 1999·European Journal of Cardio-thoracic Surgery : Official Journal of the European Association for Cardio-thoracic Surgery·E SivitanidisA Laczkovics
Apr 14, 2000·American Journal of Respiratory and Critical Care Medicine·M S KavuruJ K Stoller
Feb 17, 2001·American Journal of Respiratory and Critical Care Medicine·J F SeymourA R Dunn
Jul 20, 2001·Thorax·R M Barraclough, A J Gillies
Jan 24, 2002·Heart & Lung : the Journal of Critical Care·Ron Ben-AbrahamIssahar Ben-Dov
Jul 18, 2002·American Journal of Respiratory and Critical Care Medicine·John F Seymour, Jeffrey J Presneill
Dec 25, 2002·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Tracey L BonfieldMary Jane Thomassen
Jan 11, 2003·Internal Medicine·Toshihiko Hashizume
Mar 29, 2003·American Journal of Respiratory and Critical Care Medicine·Mani S KavuruMary J Thomassen
Jun 5, 1958·The New England Journal of Medicine·S H ROSENA A LIEBOW
May 1, 1959·Australasian Annals of Medicine·C McDOWELLJ R HINDS
Nov 9, 1961·The New England Journal of Medicine·I BRODSKY, R L MAYOCK
Sep 1, 1963·Archives of Internal Medicine·J RAMIREZR E DUTTON
Dec 26, 2003·The New England Journal of Medicine·Bruce C TrapnellKoh Nakata
Apr 16, 2004·The European Respiratory Journal·M BeccariaI Cerveri
Mar 1, 2005·American Journal of Respiratory and Critical Care Medicine·Ryushi TazawaToshihiro Nukiwa
Mar 2, 2006·The European Respiratory Journal·M E WylamP M Anderson
Mar 28, 2007·Orphanet Journal of Rare Diseases·Michele CerutiMaurizio Luisetti
Apr 7, 2007·Heart, Lung & Circulation·Birla Roy D Gnanamuthu, John Tharion
Nov 22, 2007·AJR. American Journal of Roentgenology·Edson MarchioriArthur Soares Souza

❮ Previous
Next ❯

Citations

Jan 19, 2012·Lipids in Health and Disease·Cun S FangMing Y Zhang
Nov 30, 2010·Orphanet Journal of Rare Diseases·Amelia BarilliValeria Dall'Asta
Oct 2, 2013·Orphanet Journal of Rare Diseases·Bruce C Trapnell, Maurizio Luisetti
Mar 19, 2013·Orphanet Journal of Rare Diseases·Ilaria CampoMaurizio Luisetti
Sep 11, 2012·Multidisciplinary Respiratory Medicine·Ilaria CampoMaurizio Luisetti
Sep 8, 2011·Experimental Lung Research·Xiaodan WuChunxue Bai
Jun 30, 2012·Revue des maladies respiratoires·F VincentUNKNOWN Groupe de recherche en réanimation respiratoire en onco-hématologie
May 3, 2012·Diagnostic Cytopathology·Trisha M Shattuck, Sarah M Bean
Jul 22, 2014·Revista portuguesa de pneumologia·A SilvaC Fiuza
Apr 22, 2015·Archivos de bronconeumología·José Antonio Rodríguez Portal
Jan 27, 2015·Annual Review of Pathology·Jeffrey A WhitsettTimothy E Weaver
Jul 12, 2016·Chest·Ilaria CampoUNKNOWN WLL International Study Group
Sep 1, 2016·Orphanet Journal of Rare Diseases·Ilaria CampoUNKNOWN WLL International Study Group
Dec 22, 2012·Expert Review of Clinical Immunology·Donald C Vinh, Marcel A Behr
Oct 31, 2019·Yeungnam University Journal of Medicine·Seung Won RaSe Hun Park
Jan 19, 2013·Journal of Bronchology & Interventional Pulmonology·Naveed HasanMani S Kavuru
Jun 23, 2020·Journal of Bronchology & Interventional Pulmonology·Daniel C VisPaul R MacEachern
Jul 15, 2015·Journal of Bronchology & Interventional Pulmonology·Basem B AbdelmalakMarc J Popovich
Jan 15, 2013·Clinical Chemistry and Laboratory Medicine : CCLM·Shen-Cun FangYing-Ming Zhang
Aug 15, 2014·Experimental and Therapeutic Medicine·Xiaoyan ZhouTao Bian
Aug 17, 2018·Pediatric Emergency Care·Seda Sirin KoseOzden Anal

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.